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Background: Contralateral breast cancer is either a metastatic lesion or the second primary
cancer. From biological and therapeutic viewpoints, it is important to differentiate metastatic
lesions from second primary cancer in bilateral breast cancer.
Methods: Based on Chaudary’s histological criteria, we analysed the tumors in 14 and 27
patients with synchronous and metachronous bilateral breast cancers with full histological and
biological evaluations. The Nottingham combined histological grade and immunohistochemis-
try (IHC) for the estrogen receptor, progesterone receptor and cerbB-2 were used.
Results: The median age of the patients at first diagnosis was 41 years (range, 26–68
years) and the median time interval between first and second tumors was 34 months (range;
7–209 months) in metachronous cancers. The histopathological type was found in 93% of
synchronous cancers and 59% of metachronous cancers (P ¼ 0.02). The concordance rates
of T stage and TNM stage were 71 and 64% respectively in synchronous cancers, while they
were 24 and 32% respectively in metachronous cancers (P ¼ 0.03). For progesterone recep-
tor status, the concordance rates were 86 and 52% in synchronous and metachronous
cancers respectively (P ¼ 0.03). In addition, there was no statistically significant difference in
terms of N stage, histological grade, intraductal component, estrogen receptor status, or
cerbB-2 expression.
Conclusion: In spite of the limitation of Chaudary’s criteria and the number of patients
involved, the combination of histopathological type, T stage and TNM stage shows that syn-
chronous cancers are closer to same clonal lesions (metastatic lesions) than metachronous
cancers and that a biomarker, such as progesterone receptor status, plays a role in addition
to the histological parameters in differentiating metastatic cancers from second primary
cancers.
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INTRODUCTION
Bilateral breast cancer has an overall incidence of 4–20% in
patients with primary operable breast cancer (1). The risk
factors associated with bilateral occurrence are: familial or
hereditary breast cancer, young age at primary breast cancer
diagnosis, lobular invasive carcinoma, multicentricity and
radiation exposure (1,2).
Contralateral breast cancer is either a metastatic lesion or
the second primary cancer, and occurs either synchronously
or metachronously. Chaudary et al. (3) categorized
contralateral breast cancer into a metastatic lesion or second
primary cancer based only on pathologic criteria.
Several reports showed that the prognosis in bilateral
breast cancer was worse than that of unilateral breast cancer
(4–7). There have also been many debates regarding biologi-
cal and therapeutic aspects of bilateral breast cancers (8,9).
Considering these points, it is important to know whether
contralateral breast cancer is a metastatic lesion or the
second primary cancer.
In the late 1990s the cDNA microarray-based compara-
tive genomic hybridization (CGH) method has been
employed to investigate the clonality of bilateral breast
cancers and it showed higher DNA copy number changes
in metachronous than in synchronous bilateral breast
cancers (10). However, this method is complicated,
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expensive and needs further validation for general use.
Therefore, although a caveat of the pathologic criteria of
Chaudary is that a synchronous bilateral breast cancer is
considered as a metastatic lesion and not a multifocal
monoclonal lesion, this criterion is simple and easily avail-
able in clinical practice.
In addition to genetic and pathological features, biological
features have been evaluated as well. Some researchers
reported that histological and biological features in synchro-
nous bilateral breast cancers were similar (11,12). However,
there are still controversies about the patterns of biological
phenotypes in metachronous cancers (13,14).
The aim of this study was to analyse the concordance
rates of histological and biological parameters that are easily
accessible in synchronous and metachronous bilateral breast
cancers and thus to differentiate a metastatic lesion from the
second primary cancer in bilateral breast cancer.
PATIENTS AND METHODS
PATIENTS
Among the 4702 patients diagnosed with breast cancer from
1974 to 2003 at Yonsei Cancer Center, Yonsei University
College of Medicine, 73 patients were diagnosed with bilat-
eral breast cancer without any systemic lesions. From these
patients, 41 patients were enrolled (14 synchronous, 27 meta-
chronous) with full evaluation for histological and biological
phenotypes from archive parafﬁn blocks. Contralateral breast
lesions were examined by breast ultrasonography and cancer
was conﬁrmed histologically.
Bilateral breast cancer was deﬁned as synchronous when
contralateral cancer was identiﬁed within 6 months after the
ﬁrst breast cancer (1). Contralateral breast cancer, diagnosed
with the interval of more than 6 months, was deﬁned as
metachronous bilateral breast cancer.
The overall median age of the patients at the time of diag-
nosis of the ﬁrst breast cancer was 41 years (range, 26–68
years). The median time intervals between the ﬁrst and the
subsequent breast cancer diagnosis were 0 months and 34
months (range; 7–209 months) in synchronous and meta-
chronous cancers, respectively. The characteristics of the
patients are summarized in Table 1.
HISTOLOGICAL EVALUATION
The parafﬁn-embedded tumor sections were analysed accord-
ing to the Nottingham combined histological grade
(Elston-Ellis modiﬁcation of the Scarff-Bloom-Richardson
grading system) after staining with hematoxyline and eosin
(15). The histological grade was not scored in eight tumors
of medullary and lobular type. Intraductal components
(IDCs) were not checked in four lobular type tumors and
three mucinous type tumors.
IMMUNOHISTOCHEMISTRY FOR STEROID RECEPTOR STATUS AND
cerbB-2 EXPRESSION
For immunohistochemistry (IHC), deparafﬁnized sections
were immunostained with primary antibodies to estrogen
receptor, progesterone receptor (1:50; Novocastra,
Newcastle, UK), and cerbB-2 oncoprotein (1:50; Dako, CA,
USA). In negative controls, distilled water was applied as a
substitute for primary antibodies. Sections were subjected to
heat-induced epitope retrieval for 20 min in a citrate buffer
(pH 6.0), using a microwave (800 W) and a pressure cooker.
Antigens were localized using a labeled streptavidin method
(Universal LSAB2 kit, Dako) with 3,30-diaminobenzidine as
a chromogen (16).
In estrogen and progesterone receptor stain, a 20% nuclear
positivity rate was regarded as receptor positive (17).
Distinct membrane staining was considered to be speciﬁc for
cerbB-2 gene expression (18). Two positive (þþ, a weak to
moderate membrane staining is observed in more than 10%
of the tumor cells) and three positive (þþþ, a strong com-
plete membrane staining is observed in more than 10% of
the tumor cells) were regarded as cerbB-2 expression
positive.
STAGING OF BREAST CANCER
Cancer staging was done in all bilateral breast cancer
patients by AJCC criteria (19).
STATISTICAL METHODS
Student’s t-test was used for the analysis of group com-
parison with histologic and biologic parameters.
Correlation between variables was estimated with Pearson’s
correlation. Statistical values of P, 0.05 were considered
as signiﬁcant.
Table 1. Patient characteristics of bilateral breast cancer
Variable Synchronous
(n ¼ 14)
Metachronous
(n ¼ 27)
1st tumor 2nd tumor 1st tumor 2nd tumor
Age at diagnosis (yr),
[median (range)]
47 (28–64) 39 (26–68) 44 (28–70)
Time-interval of different
tumors (yr), [median
(range)]
0 34 (7–209)
Stage
O 0 0 4 1
I 0 3 1 11
II 8 6 19 12
III 6 5 3 1
IV 0 0 0 2
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RESULTS
HISTOLOGICAL DIFFERENCES IN BILATERAL BREAST CANCER
The most common histopathological type was inﬁltrating
ductal carcinoma (78% in all) (Table 2). The rates of the
same histopathological type were 93% in synchronous
cancers but only 59% in metachronous cancers (P ¼ 0.02)
(Fig. 1). The concordance rates of histological grade were
50% in synchronous cancers and 33% in metachronous
cancers (Fig. 1). The rate that tumors belonged to the high
intraductal component (IDC) group was 20% in two tumors
of synchronous cancer and 16% in second tumors of meta-
chronous cancer (Table 2).
STAGING DIFFERENCES IN BILATERAL BREAST CANCER TISSUE
The concordance rates of T stage, N stage and TNM stage
were seen to be 71, 79 and 64% respectively in synchronous
cancers whereas they were 24, 74 and 32% respectively, in
metachronous cancers. T stages and TNM stages are more
diverse in metachronous cancers than in synchronous cancers
(P ¼ 0.03) (Fig. 1).
STEROID RECEPTOR STATUS IN BILATERAL BREAST
CANCER TISSUE
In synchronous cancers, the concordance rate of estrogen
receptor expression was 71% and that of progesterone
receptor was 86%. However, in metachronous cancers, the
concordance rates of both estrogen and progesterone receptor
expression were 52% (Fig. 2). In terms of progesterone
receptor status, the difference in the concordance rates of
expression in synchronous and metachronous cancers was
signiﬁcant (P ¼ 0.03) (Fig. 2).
The positivity of steroid receptor status was evaluated
according to the age of the patient. In synchronous cancers,
patients older than 50 years showed higher estrogen receptor
positivity (71%) than those under 50 years old (P ¼ 0.02)
(Table 3). Progesterone receptor status in synchronous and
metachronous cancers, and estrogen receptor status in meta-
chronous cancers were not signiﬁcantly different between
the two age groups.
COMPARISON OF cerbB-2 GENE EXPRESSION IN BILATERAL
BREAST CANCER TISSUE
In synchronous cancers, cerbB-2 expression was concordant
in 71% of patients: both positive, 29% and both negative,
43% (Fig. 2, Table 4). In metachronous cancers, the concor-
dance rate was 63% (Fig. 2, Table 4).
DISCUSSION
In bilateral breast cancer, it is important to know whether
contralateral breast lesion is metastatic or second primary,
but the distinction is not always easy. Chaudary et al. (3)
proposed criteria for the diagnosis of second primary breast
cancer in 1984 as follows: (i) there must be in situ change in
the contralateral tumor, (ii) the tumor in the second breast is
histologically different from the cancer in the ﬁrst breast,
(iii) the degree of histological differentiation of the tumor in
the second breast is distinctly greater than that of the lesion
in the ﬁrst breast, (iv) there is no evidence of local, regional,
or distant metastases from the cancer in the ipsilateral breast.
Despite novel methods such as cDNA microarray-based
CGH, Chaudary’s criteria have been hitherto the most
widely accepted method to distinguish second primary lesion
from metastatic lesion. Using these criteria, we attempted to
characterize synchronous and metachronous bilateral breast
cancers.
The concordance rates of histopathologic type were 93%
and 59% in synchronous and metachronous cancers respect-
ively (P ¼ 0.02). In terms of the tumor grade and in situ
change, no signiﬁcant differences were found between syn-
chronous and metachronous cancers. The proportion of the
patients with the same T and TNM stages between the ﬁrst
and the second tumors is higher in synchronous cancers than
in metachronous cancers (P ¼ 0.03). These results show that
synchronous cancers are more of the same clonal origin than
metachronous ones in Asian bilateral breast cancer, which
has low compared with its prevalence in Western countries,
and was in accordance with the results of large scale Korean
studies (20).
Table 2. Characteristics of histological parameters in bilateral breast
cancers
Variable Synchronous
(n ¼ 14)
Metachronous
(n ¼ 27)
1st tumor 2nd tumor 1st tumor 2nd tumor
Histopathologic type
IDC1 12 11 18 23
DCIS2 0 0 3 1
medullary ca. 0 0 3 1
lobular ca. 1 1 1 1
tubular 1 1 0 0
mucinous 0 1 1 1
papillary 0 0 1 0
Histological grade3
1 1 2 2 6
2 6 5 14 9
3 6 5 6 9
Intraductal component4
0–50% 11 9 19 21
50–100% 2 3 6 4
1Inﬁltrating ductal carcinoma. 2Ductal carcinoma in situ. 3Not scored in
medullary and lobular type. 4Not checked in lobular and mucinous type.
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Steroid receptor expressions in bilateral breast cancers
have been evaluated in several reports (11–14). Some
authors have found that the concordance rate of estrogen
receptor level and its positivity rate are high in synchronous
cancers (11,12). In our study, no differences were found in
the concordance rate of estrogen receptor expression in syn-
chronous and metachronous bilateral breast cancers.
However, the concordance rate of progesterone receptor
expression was signiﬁcantly higher in synchronous cases
(P ¼ 0.03). Considering the results of previous studies and
the positive regulation of progesterone receptor expression
by estrogen (21), the results of steroid hormone receptor
expression in this study show that further validation in a
large-scale study is required.
The steroid hormone receptor expression was more com-
monly negative in synchronous cancers than in metachronous
cancers. Because the steroid hormone receptor expression in
breast cancer is age dependent (22), we compared the
hormone receptor expression between the patients younger
and older than 50 years. Estrogen receptor positivity was
higher in patients over 50 years old than in those under 50
years in synchronous cancers (P ¼ 0.02). These ﬁndings are
in accordance with one of the explanations of bilaterality in
breast cancer; namely hormone dependence. In metachro-
nous cancers, signiﬁcant differences of the estrogen receptor
expression rate were not found between the two age groups.
Relatively long periods between the diagnosis of the ﬁrst
tumor and the second tumor may contribute to this result;
ﬁve of 27 patients with metachronous bilateral breast cancers
had the ﬁrst breast cancer before the age of 50 and the
second breast cancer after the age of 50. Moreover, adminis-
tration of tamoxifen for the treatment of the ﬁrst breast
Figure 1. Concordance rates (%) of histologic parameters in synchronous and metachronous bilateral breast cancers. IDC, intraductal component.
Figure 2. Concordance rates (%) of biologic parameters in synchronous and metachronous bilateral breast cancers.
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cancer might inﬂuence estrogen receptor status in contralat-
eral breast cancer (23,24). In this small number of patients,
the tamoxifen effect on estrogen receptor expression of the
subsequent breast cancer was not conclusive in a subgroup
analysis.
Several genetic alterations had been identiﬁed in breast
cancer (20): p53 and cerbB-2 expression were investigated in
bilateral breast cancers (25–29). cerbB-2 protein overexpres-
sion is more common in ductal cancer in situ (DCIS) than in
inﬁltrating ductal carcinoma, suggesting that cerbB-2 gene
ampliﬁcation is an early event of breast cancer development.
In the present study, staining for cerbB-2 was positive in
44% of all tumor tissues, regardless of the ﬁrst or the second
tumors, which was higher than the cerbB-2 expression rate
of about 26% in unilateral breast cancer (30). Safar et al.
(29) produced similar results and suggested that, in compari-
son with the unilateral breast cancer, the increased mortality
of patients with bilateral synchronous breast cancer may be
associated with the higher rate of cerbB-2 overexpression.
Van Agthoven et al. (31) investigated EGFR expression in
bilateral breast cancer tissues and found no signiﬁcant corre-
lation between EGFR expression and the interval between
the ﬁrst and second tumors. We also were unable to ﬁnd
differences of the cerbB-2 expression rate between synchro-
nous and metachronous breast cancer tissues.
The concordance rates of histopathological type, T stage,
TNM stage and progesterone receptor expression were sig-
niﬁcantly higher in synchronous cancers than in metachro-
nous bilateral breast cancers (P ¼ 0.032). That means
synchronously developed pairs of bilateral breast cancers are
biologically closer than metachronous bilateral breast
cancers. Accordingly, with respect to treatment strategies,
synchronous bilateral breast cancers can be considered as the
same origin but treatment for metachronous bilateral breast
cancers should be individualized.
Although this study is limited owing to the number of
patients involved, this report shows that biological marker
can be an indicator in addition to the histological factors in
order to differentiate metastatic cancer from second primary
cancer in synchronous and metachronous bilateral cancers of
the breast.
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